Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

Abstract

The ARQ 197-215 study randomized patients to tivantinib or placebo and pre-specified efficacy analyses indicated the predictive value of MET expression as a marker of benefit from tivantinib in hepatocellular carcinoma (HCC). We aimed to explore the neutrophil-to-lymphocyte ratio (NLR) in 98 ARQ 197-215 patients with available absolute neutrophil count and… (More)
DOI: 10.18632/oncotarget.14797

Topics

3 Figures and Tables

Cite this paper

@inproceedings{Personeni2017PrognosticVO, title={Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma}, author={Nicola Personeni and Laura Giordano and Giovanni Abbadessa and Camillo Porta and Ivan Borbath and Bruno Daniele and Jean-Luc Van Laethem and Hans Van Vlierberghe and Joerg Trojan and Enrico Narciso De Toni and Antonio Gasbarrini and Monica Lencioni and Maria E. Lamar and Yunxia Wang and Dale E Shuster and Brian Schwartz and Armando Santoro and Lorenza Rimassa}, booktitle={Oncotarget}, year={2017} }